Shares in BARD1 Life Sciences have more than doubled, after the diagnostics business revealed its SubB2M technology can be used to detect all stages of breast cancer.
Shares in BARD1 Life Sciences have more than doubled, after the diagnostics business revealed its SubB2M technology can be used to detect all stages of breast cancer.
BARD1, which merged with Victorian medtech business Sienna Cancer Diagnostics in April last year, is focused on commercialising cancer diagnostic solutions for healthcare professionals and patients.
Today, the formerly Perth-based business announced that additional data related to SubB2M – released by Griffith University’s Institute for Glycomics – showed the tech could detect all stages of breast cancer with 100 per spent specificity and more than 95 per cent sensitivity.
BARD1’s shares closed up 103.5 per cent on the news to trade at $3.50. By comparison, the business was trading at 66 cents at the beginning of the year.
Griffith’s findings also showed the potential of SubB2M in monitoring patients for disease recurrence, its usefulness as a diagnostic marker for the detection of early-stage breast cancer, and as a tool for monitoring disease progression in late-stage cancer.
It comes four days after Griffith research showed that SubB2M could detect all stages of ovarian cancer with 100 per cent specificity and 100 per cent sensitivity.
BARD1 chief executive Leearne Hinch said the SubB2M technology showed its potential for the development of tests for monitoring and detection of multiple cancers.
“A non-invasive, accurate and reliable blood test for monitoring breast cancer has the potential to enable earlier detection, inform treatment decisions and improve health outcomes for women diagnosed with this deadly cancer,” she said.
BARD1, now based in Melbourne, plans to develop and commercialise SubB2M-based blood tests to monitor patients diagnosed with breast cancer for treatment response and recurrence.
The outcomes from those studies are expected by September 30.
The business also expects its SubB2M technology can be used to improve the specificity of existing commercial diagnostic tests, potentially enabling the development and commercialisation of fast-to-market blood tests such as the PSA test for prostate cancer.
